Back to News Page
Source: MedTech Dive
MedTech Dive covers Boomerang Ventures’ strategic pre-seed investment in IMPOWER HEALTH and the appointment of Trent McCracken as CEO. IMPOWER HEALTH’s patented software transforms standard treadmills into lab-grade gait diagnostic tools, enabling objective, reimbursable mobility insights without wearables or cameras.
Source: AP News
AP News reports that Boomerang Ventures has led a strategic pre-seed investment in IMPOWER HEALTH and appointed Trent McCracken as CEO. The company’s patented platform transforms standard treadmills into lab-grade gait diagnostic tools, enabling objective, reimbursable mobility insights across rehabilitation, performance, and preventive health settings.
Boomerang Ventures has led a strategic pre-seed investment in IMPOWER HEALTH, a mobility health startup transforming treadmills into clinical-grade gait diagnostics platforms. The Omaha-based company also appointed Trent McCracken as CEO as it advances commercialization and OEM partnerships. IMPOWER HEALTH’s technology captures objective, reimbursable gait variability data across rehabilitation and performance-focused fitness settings, positioning mobility as a measurable clinical biomarker.
Boomerang Ventures has announced a seed-stage investment in SynchNeuro, a pioneering neurotechnology company developing the world’s first brain-based, non-invasive continuous glucose monitor. The partnership accelerates SynchNeuro’s mission to revolutionize cardiometabolic health through EEG-based technology that interprets brain signals to track blood glucose and other vital metrics in real time. This innovative approach aims to make proactive, pain-free, and affordable glucose monitoring accessible to millions.
Back to News Page
